Takeda picks first woman as CEO of centuries-old drugmaker
Julie Kim has been running Takeda’s US operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval.
BioSpace2h
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...
Takeda’s next CEO is a familiar face in Massachusetts biotech scene
When Takeda CEO Christophe Weber retires from the company in June 2026, a familiar face among the Massachusetts biotech scene will take over leading the Japanese pharma giant.
Takeda gains after FY24 guidance raise, CEO transition
Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.
ジャパンタイムズ12h
Takeda picks first female CEO of centuries-old drugmaker
Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...
Takeda CEO Christophe Weber to retire in 2026, Julie Kim to succeed
Takeda (TAK) announced that its board of directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S.